More on AKTS
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $24.79 |
|
|||
| Open | $24.41 | ||||
| 52 Wk High | $5.77 | ||||
| 52 Wk Low | $1.51 | ||||
| Day High | $27.50 | ||||
| Day Low | $24.36 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 408,079 | ||||
- Raymond James Starts Aktis Oncology (AKTS) at Strong Buy (correction)
- Akoustis Technologies (AKTS) PT Raised to $35 at H.C. Wainwright
- Aktis Oncology to Present at the Jefferies Global Healthcare Conference
- Aktis reports imaging data for cancer drug targeting B7-H3 protein
- Aktis Oncology Reports First-in-Human Clinical Imaging and Dosimetry Data for AKY-2519 Demonstrating Robust Tumor Uptake and Limited Normal Tissue Exposures in Patients with B7-H3 Expressing Tumors
- Aktis Oncology Reports Financial Results and Business Highlights for First Quarter 2026
- Aktis Oncology to Present at the BofA Securities Health Care Conference
- Aktis Oncology starts Phase 1b trial for prostate cancer drug AKY-2519
- Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519, a B7-H3 Miniprotein Radioconjugate, in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Two River and Vida Ventures Extend Track Record of Company Creation and Value Realization Following the Candid Therapeutics’ Acquisition by UCB
Entities mentioned with AKTS
- Definitive Agreement | View Related Stories »
- Roth Capital | View Related Stories »
- Earnings | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- S3 | View Related Stories »
- Show More...
